⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18537453 | 0.72 | — | — | |
| SCHEMBL1240685 | 0.69 | — | — | |
| SCHEMBL1471362 | 0.69 | — | — | |
| SCHEMBL1029536 | 0.67 | — | — | |
| SCHEMBL11648258 | 0.67 | — | — | |
| SCHEMBL23199594 | 0.67 | — | — | |
| SCHEMBL13833790 | 0.67 | — | — | |
| SCHEMBL11648789 | 0.67 | — | — | |
| SCHEMBL8812438 | 0.67 | — | — | |
| SCHEMBL28599095 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351502-B2 | Method for producing α,α-difluoroacetaldehyde | CENTRAL GLASS COMPANY, LIMITED (JP) | 2019-07-16 | — | — | US | claimed |
| US-20190031587-A1 | Method for Producing Alpha, Alpha-Difluoroacetaldehyde | CENTRAL GLASS COMPANY, LIMITED (JP) | 2019-01-31 | — | — | US | claimed |
| EP-3398929-A1 | METHOD FOR PRODUCING , -DIFLUOROACETALDEHYDE | Central Glass Company, Limited (JP) | 2018-11-07 | — | — | EP | claimed |
| US-20240186520-A1 | RESIN COMPOSITION FOR SECONDARY BATTERY ELECTRODE | SEKISUI CHEMICAL CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| US-20240166595-A1 | PROCESS FOR THE PREPARATION OF BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS | GENENTECH, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| CN-114736104-B | Synthesis method of difluoroacetaldehyde hemiethanol | 上海恩氟佳科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4347574-A1 | PROCESS FOR THE PREPARATION OF BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS | Genentech, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4317203-A1 | RESIN COMPOSITION FOR SECONDARY BATTERY ELECTRODE | SEKISUI CHEMICAL CO., LTD. (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117377660-A | Process for the preparation of benzoxazepine oxazolidinone compounds | 基因泰克公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-3871673-B1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-01-03 | — | — | EP | disclosed |
| CN-116813596-A | Macrocyclic HCV NS3 inhibits tripeptide synthesis | 吉利德科学公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20030232863-A1 | Such as N1-(1-cyanocyclopropyl)-4-fluoro-N2-((1S)-2,2,2-trifluoro-1-(4' -(methylsulfonyl)-1,1'-biphenyl-4-yl) ethyl)-L-leucinamide; for treating osteoporosis and other bone loss disorders | BAYLY CHRISTOPHER I (CA) | 2003-12-18 | — | — | US | disclosed |
| WO-2003075836-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-09-18 | — | — | WO | disclosed |
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1252178-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002050056-A1 | BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002006272-A1 | POLYFLUOROALKYLTRIAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |